Affimed to Present at the Jefferies Virtual Healthcare Conference
May 28 2020 - 5:00AM
Heidelberg, Germany, May 28, 2020 –
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that its Chief Executive Officer, Dr.
Adi Hoess, will present at the Jefferies Virtual Healthcare
Conference on Wednesday, June 3, 2020 at 8:00 a.m. Eastern
Time.
A live webcast of the presentation can be
accessed under the “Investors” section of Affimed’s website
at https://www.affimed.com/investors/webcasts_cp/ and
will be available for 30 days following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors. For more information, please
visit www.affimed.com.
Affimed Investor Contact
Alexander Fudukidis, Head of Investor
RelationsE-Mail: IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024